offline
Pfizer's COVID product sales to top $50 billion this year, investors want more
By Manas Mishra and Michael Erman
(Reuters) - Pfizer Inc said on Tuesday it expects 2022 sales of its COVID-19 vaccine and antiviral pill to top $54 billion, but that fell short of lofty Wall Street estimates and its shares were off about 3%.
Still, Chief Executive Albert Bourla said final sales for its oral COVID-19 antiviral, Paxlovid, could be "way bigger" than what Pfizer has forecast since its current outlook only included contracts that have been or are close to being signed.
Pfizer currently expects $22 billion in 2022 sales of the treatment, compared with Wall Street estimates of $22.88 billion.
"Clearly, this is only a fraction of the 120 million treatments that we are right now preparing to manufacture" this year, Bourla told analysts on a conference call.
The company is selling 20 million courses of Paxlovid to the United States at around $530 a course, but Bourla said that was a special price because of the size of the order.
...
https://finance.yahoo.com/news/pfizer-fo...21711.html
![[Bild: PFEw155682869i.png]](https://finviz.com/publish/020822/PFEw155682869i.png)
By Manas Mishra and Michael Erman
(Reuters) - Pfizer Inc said on Tuesday it expects 2022 sales of its COVID-19 vaccine and antiviral pill to top $54 billion, but that fell short of lofty Wall Street estimates and its shares were off about 3%.
Still, Chief Executive Albert Bourla said final sales for its oral COVID-19 antiviral, Paxlovid, could be "way bigger" than what Pfizer has forecast since its current outlook only included contracts that have been or are close to being signed.
Pfizer currently expects $22 billion in 2022 sales of the treatment, compared with Wall Street estimates of $22.88 billion.
"Clearly, this is only a fraction of the 120 million treatments that we are right now preparing to manufacture" this year, Bourla told analysts on a conference call.
The company is selling 20 million courses of Paxlovid to the United States at around $530 a course, but Bourla said that was a special price because of the size of the order.
...
https://finance.yahoo.com/news/pfizer-fo...21711.html
__________________
